A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

Cancer
Rupal S BhattVikas P Sukhatme

Abstract

: Tumor angiogenesis has been associated with a poor prognosis in patients with metastatic melanoma (MM). Microtubule stabilizers and cyclooxygenase 2 (COX-2) inhibitors, alone and in combination, have produced inhibitory effects on endothelial cells and tumor angiogenesis. Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM. : Patients received paclitaxel 10 mg/m(2) for 96 hours weekly as a continuous intravenous infusion and oral celecoxib 400 mg twice daily. Systemic tumor response was assessed at 6-week intervals. Tumor measurements at the end of Cycle 1 were used as the baseline for assessment of tumor progression. Patients with unacceptable toxicity or disease progression after Cycle 2 relative to the end of Cycle 1 were taken off study. : Twenty patients were enrolled. Twelve of 20 patients (60%) had received > or =2 previous systemic therapies. Three patients did not receive treatment because of rapid disease progression. Treatment-related grade 3/4 toxicities were limited to catheter-related complications. One patient achieved a partial response, and 3 of 20 p...Continue Reading

References

Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S UgurelU Reinhold
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ F Thompson
Oct 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Guido BocciRobert S Kerbel
May 22, 2004·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Bo LennernäsKlas Norrby
Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Jaime R MerchanVikas P Sukhatme
Feb 22, 2005·Lancet·John F ThompsonRichard F Kefford
Jun 14, 2005·Lancet·Spyros Retsas
Jun 14, 2005·Lancet·Vincenzo de GiorgiPaolo Carli
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sylvia S W NgRobert S Kerbel
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anat Norden-ZfoniJohn V Heymach
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Natalie J IvesKeith Wheatley
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottEvan Hersh

❮ Previous
Next ❯

Citations

Feb 21, 2013·Cancer Immunology, Immunotherapy : CII·Rupal Ramakrishnan, Dmitry I Gabrilovich
Sep 6, 2013·Current Oncology Reports·Aaron S Mansfield, Svetomir N Markovic
Feb 20, 2013·Clinical Pharmacokinetics·Frederik E StuurmanJan H M Schellens
Jun 10, 2010·Nature Reviews. Clinical Oncology·Eddy PasquierNicolas André
May 11, 2012·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Cheryl M Coffin, Rita Alaggio
Mar 23, 2011·Future Oncology·Sarah J L Payne, Louise Jones
Jun 11, 2014·Nature Reviews. Clinical Oncology·Nicolas AndréEddy Pasquier
Mar 12, 2013·Cancer Chemotherapy and Pharmacology·Adriana RomitiPaolo Marchetti
Oct 19, 2011·Journal of Oncology·Una AdamcicBrenda L Coomber
Sep 17, 2014·Biomarkers in Medicine·Gemma CramarossaUrban Emmenegger
Feb 13, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hee Jung KimYoung Tae Kim
Feb 16, 2013·Melanoma Research·Alessandro M MinisiniCarla Di Loreto
Oct 25, 2014·International Journal of Molecular Sciences·Wei LiJane Wang
Aug 30, 2011·Journal of the Chinese Medical Association : JCMA·Peng-Hui Wang, Bor-Ching Sheu
Oct 23, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Johannes MoesBastiaan Nuijen
Jul 19, 2011·Toxicology and Applied Pharmacology·Raafat A El-AwadyAbeer M Elsayed
Dec 3, 2010·The Journal of Pathology·Michael Allen, J Louise Jones
Jul 3, 2015·BioMed Research International·Nirmala Chandralega KampanMagdalena Plebanski
Oct 24, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Guang-Yu TianXin-En Huang
Feb 7, 2015·Critical Reviews in Oncology/hematology·Antonio GnoniVito Lorusso
May 2, 2018·Current Cancer Drug Targets·Oliesia Gonzalez Quiñones, Maria Bernadete Riemma Pierre
Apr 28, 2017·PloS One·Laila RitsmaSridhar Ramaswamy
Apr 25, 2019·Journal of Oncology·Cem SimsekSuayib Yalcin
Feb 12, 2020·Scientific Reports·Nirmala Chandralega KampanMagdalena Plebanski
Dec 1, 2020·Critical Reviews in Oncology/hematology·Palma FedeleSaverio Cinieri
May 1, 2021·International Journal of Molecular Sciences·Diana Valentina TudorGabriela Adriana Filip
Aug 18, 2017·Molecular Pharmaceutics·Lauren J JablonowskiMargaret A Wheatley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved